Analyst Ratings for Iovance Biotherapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) received 7 bullish, 4 somewhat bullish, and 2 indifferent analyst ratings. The average price target is $24.31, a significant increase from the previous target of $19.60, implying upside potential.
June 15, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics received positive analyst ratings in the last quarter, with an average price target of $24.31, up from $19.60, indicating potential upside.
The positive analyst ratings and increased average price target for Iovance Biotherapeutics suggest that the stock has potential for growth in the short term. The 24.03% increase in the average price target from $19.60 to $24.31 indicates that analysts are more bullish on the stock, which could lead to an increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100